Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Next Previous
Trial Profile

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MBK-103 (Primary) ; Bevacizumab; Carboplatin
  • Indications Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Fallopian tube cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Eli Lilly and Company; Mablink Bioscience

Most Recent Events

  • 02 Jun 2025 Results presented in an Eli Lilly and Company media release
  • 02 Jun 2025 According to an Eli Lilly and Company media release, data cutoff: as of 9 Mar 2025, study enrolled 95 participants with high-grade serous ovarian cancer across four dose levels (2 - 6 mg/kg).
  • 02 Jun 2025 According to an Eli Lilly and Company media release, new phase 1 data from this trial were presented in a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top